Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
7.68
-0.15 (-1.92%)
Feb 21, 2025, 4:00 PM EST - Market closed
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 21.2, with a low estimate of 17 and a high estimate of 25. The average target predicts an increase of 176.04% from the current stock price of 7.68.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 20, 2024.
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +160.42% | Nov 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $23 | Strong Buy | Maintains | $25 → $23 | +199.48% | Nov 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 11, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +160.42% | Sep 30, 2024 |
Financial Forecast
Revenue This Year
20.93M
from 27.46M
Decreased by -23.80%
Revenue Next Year
89.99M
from 20.93M
Increased by 330.04%
EPS This Year
-2.03
from -1.30
EPS Next Year
-0.34
from -2.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 24.7M | 110.2M | 222.6M | |||
| Avg | 20.9M | 90.0M | 178.2M | |||
| Low | 17.2M | 58.5M | 145.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -9.9% | 426.6% | 147.4% | |||
| Avg | -23.8% | 330.0% | 98.0% | |||
| Low | -37.2% | 179.6% | 61.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.02 | 1.26 | 1.42 | |||
| Avg | -2.03 | -0.34 | 0.78 | |||
| Low | -2.10 | -1.31 | 0.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.